CINECA IRIS Institutional Research Information System

VALABREGA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.580
EU - Europa 3.606
AS - Asia 2.462
SA - Sud America 93
AF - Africa 87
OC - Oceania 71
Continente sconosciuto - Info sul continente non disponibili 10
Totale 11.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.423
CN - Cina 1.232
IT - Italia 1.079
GB - Regno Unito 377
IE - Irlanda 370
DE - Germania 347
SE - Svezia 278
SG - Singapore 276
FR - Francia 273
JP - Giappone 237
ES - Italia 142
IN - India 135
FI - Finlandia 125
KR - Corea 120
CA - Canada 116
VN - Vietnam 116
PL - Polonia 111
UA - Ucraina 109
ID - Indonesia 76
AU - Australia 62
NL - Olanda 61
DK - Danimarca 59
TR - Turchia 53
BE - Belgio 50
HK - Hong Kong 48
TW - Taiwan 42
BR - Brasile 41
MX - Messico 40
CH - Svizzera 36
RU - Federazione Russa 32
EG - Egitto 30
AT - Austria 27
PT - Portogallo 26
TH - Thailandia 25
IR - Iran 24
RO - Romania 24
NG - Nigeria 23
IL - Israele 21
PE - Perù 16
GR - Grecia 14
SA - Arabia Saudita 13
AR - Argentina 12
CO - Colombia 11
CZ - Repubblica Ceca 11
HR - Croazia 11
CL - Cile 10
HU - Ungheria 10
NZ - Nuova Zelanda 9
UZ - Uzbekistan 9
MY - Malesia 8
NO - Norvegia 7
AP - ???statistics.table.value.countryCode.AP??? 6
KW - Kuwait 6
MA - Marocco 6
SN - Senegal 6
TN - Tunisia 6
BY - Bielorussia 5
AM - Armenia 4
EU - Europa 4
LU - Lussemburgo 4
PK - Pakistan 4
SD - Sudan 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
BG - Bulgaria 3
EC - Ecuador 3
RS - Serbia 3
BF - Burkina Faso 2
JO - Giordania 2
LB - Libano 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
PH - Filippine 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CU - Cuba 1
EE - Estonia 1
ET - Etiopia 1
IQ - Iraq 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
QA - Qatar 1
SI - Slovenia 1
ZW - Zimbabwe 1
Totale 11.909
Salva come PNG Salva come JPEG
Città #
Chandler 626
Fairfield 448
Dublin 357
Beijing 350
Houston 346
Ashburn 329
Woodbridge 247
Ann Arbor 240
Seattle 213
Singapore 194
Wilmington 186
Cambridge 170
Torino 155
Nyköping 137
Redwood City 127
Jacksonville 102
Shanghai 101
Princeton 91
Medford 90
Villeurbanne 86
Dearborn 85
Munich 83
Guangzhou 82
New York 78
Turin 76
Jakarta 72
Milan 72
Rome 70
Warsaw 70
Pisa 67
Dong Ket 64
Nanjing 61
Tokyo 54
Boston 41
Fremont 41
London 38
Boardman 35
Hangzhou 33
San Diego 31
Chicago 28
Wuhan 28
Asyut 27
Duncan 27
Los Angeles 26
Santa Clara 26
Chengdu 25
Ottawa 25
Taipei 24
Toronto 23
Madrid 22
Brussels 21
Abuja 20
Delhi 18
Kunming 18
Hong Kong 17
Jinan 17
Paris 17
Sydney 17
Washington 17
Barcelona 16
Hefei 16
Helsinki 16
Seoul 16
Silver Spring 16
Vienna 16
Phoenix 15
Changsha 14
Hebei 14
Istanbul 14
Shenyang 14
Upper Marlboro 14
Dallas 13
Osaka 13
São Paulo 13
Tianjin 13
Worcester 13
Amsterdam 12
Harbin 12
Norwalk 12
Riverton 12
St Louis 12
Valencia 12
Xian 12
Zhengzhou 12
Ankara 11
Naples 11
Verona 11
Bangkok 10
Berlin 10
Düsseldorf 10
Glasgow 10
Gothenburg 10
Lappeenranta 10
New Delhi 10
Newcastle 10
Padova 10
Varese 10
Basingstoke 9
Birmingham 9
Central District 9
Totale 6.693
Salva come PNG Salva come JPEG
Nome #
PARP Inhibitors in Ovarian Cancer 2.589
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 718
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer 512
Metastatic breast cancer subtypes and central nervous system metastases. 288
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 253
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. 231
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity 220
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis 197
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer 189
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy 189
Androgen receptor status predicts development of brain metastases in ovarian cancers 188
Adoptive immunotherapy against ovarian cancer 172
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy 170
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions 160
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer 156
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer? 154
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. 147
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? 143
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 128
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience 126
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer 120
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers 119
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 117
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience 114
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications 113
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 112
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells 111
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy 110
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 108
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer 108
Recent advances in the development of breast cancer vaccines. 106
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 103
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity 100
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives 100
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series 99
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models 95
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma 92
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer 90
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 90
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer 87
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 87
Ovarian cancer immunotherapy: Turning up the heat 86
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 84
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs) 83
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy 80
Role of cyclin-dependent kinase inhibitors in endometrial cancer 76
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer 73
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial 71
A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. 71
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 70
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience 69
Is there a role for immunotherapy in ovarian cancer? 67
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w) 65
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 63
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 62
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 62
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer 61
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. 61
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers 61
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study 60
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 59
Veliparib: a new therapeutic option in ovarian cancer? 56
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. 55
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. 55
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality 55
Controversies in breast cancer: adjuvant and neoadjuvant therapy 53
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey 51
Biomarkers of central nervous system involvement from epithelial ovarian cancer 50
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era 49
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition 49
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 47
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time? 47
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells 47
Translational research in ovarian cancer 46
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy 46
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors 46
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 45
Immunotherapy in cervix cancer 45
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 44
Trastuzumab-based combination therapy for breast cancer 43
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 43
Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. 41
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer 41
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. 40
Trastuzumab treatment in breast cancer 40
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia 40
Multitarget drugs: the present and the future of cancer therapy 39
Trastuzumab Beyond Disease Progression: Case Closed? 38
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 37
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 37
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups 36
Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. 31
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 28
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 27
Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers 27
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. 27
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey 22
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 19
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 19
Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 18
Totale 12.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.282
article - articoli 0
book - libri 0
conference - conferenze 954
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.085 0 0 0 128 92 219 129 112 136 93 67 109
2020/20212.148 67 172 270 172 175 173 157 153 178 204 140 287
2021/20222.082 149 132 103 161 135 144 157 170 161 148 329 293
2022/20232.425 211 222 94 198 229 481 184 152 257 86 172 139
2023/20241.959 211 221 104 147 145 257 158 166 40 158 136 216
2024/2025432 72 180 149 31 0 0 0 0 0 0 0 0
Totale 12.199